Agenus Q2 2023 net loss $73.4M; bot/bal combo mOS 20.9 months in CRC, FDA Fast Track

AGENUS INC

2023-Q2 EPS reported -$0.41 revenue$48,198,000

Q2 revenue $25.3M, net loss $73.4M ($0.20 EPS); cash $157.6M at June 30, down from $193.4M at Dec 2022.
Bot/bal combo in 3L+ Non-MSI-H CRC: mOS 20.9 months vs 12.9 SOC; ORR 23% vs 2.8%; FDA Fast Track granted.
ACTIVATE Phase 2 CRC and melanoma trials on target to fully enroll by end of 2023; BLA submission planned in 2024.
AGEN2373 monotherapy shows clinical responses in prostate, ampullary, vulvar cancers; first CD137 agonist with no hepatic toxicity.
Leadership appointments: Robin Taylor (CCO), Homa Yeganegi (Chief Product Strategy & Global Medical Affairs), Stephanie Fagan (CCO).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.